MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keaf092

Медицинская библиотека · Rheumatology (Oxford, England) · 2025

Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis.

Ahmed Shyfuddin, Pfeiffer Ruth M, Jackson Sarah S, Song Minkyo, Mariette Xavier, Seror Raphaèle, Engels Eric A

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

OBJECTIVE

To examine cancer risk associated with Janus kinase inhibitors (JAKis) and biological DMARDs (bDMARDs) in patients with RA.

METHODS

Case-control study of patients with RA age 65 years or older in the US Surveillance, Epidemiology, and End Results (SEER)-Medicare database during 2014-2019. Cases were individuals with a first cancer diagnosed in SEER registries (N = 12 463). Cancer-free controls (N = 38 345) were Medicare beneficiaries residing in SEER areas. Exposure to JAKis, tumour necrosis factor inhibitors (TNFis) and other bDMARDs was ascertained using prescription claims. Logistic regression was used to estimate adjusted odds ratios (ORs).

RESULTS

1.9% of cases and 2.0% of controls were prescribed a JAKi. Among patients prescribed a JAKi, the median duration of documented exposure was 1.8 years. Overall cancer risk was not associated with exposure to JAKis (adjusted OR 1.04, 95% CI 0.87-1.26), TNFis (0.98, 0.92-1.05) or other bDMARDs (0.98, 0.90-1.07). However, JAKi exposure was associated with significantly increased risk of lung cancer (OR 1.40, 95% CI 1.06-1.87), especially in males (2.12, 1.14-3.94) and with >2 years of JAKi exposure (1.52, 1.01-2.28). Among females, JAKi exposure was associated with lower risk of breast cancer (OR 0.62, 95% CI 0.39-0.97).

CONCLUSIONS

Among older adults with RA, JAKi exposure over a median of 1.8 years was not associated with an overall increase in cancer risk. However, lung cancer risk was elevated, supporting clinical caution in prescribing this medication class to smokers. Further research is needed to understand the role of the JAK/STAT pathway in cancer.

Для цитирования: Ahmed Shyfuddin, Pfeiffer Ruth M, Jackson Sarah S, Song Minkyo, Mariette Xavier, Seror Raphaèle, Engels Eric A. Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis.. Rheumatology (Oxford, England). 2025. DOI: 10.1093/rheumatology/keaf092.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.